Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

NCT02956772 is registered in ClinicalTrials.gov with Hunan Provincial People's Hospital as lead sponsor.

NCT NCT02956772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02956772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Lead sponsor
Hunan Provincial People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2016
Completion date
November 30, 2020
Enrollment
190 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

primary hepatocellular carcinoma